text: SECTION 1. SHORT TITLE.
  
      This Act may be cited as the ``Heart Disease Education, Analysis, 
  Research, and Treatment for Women Act'' or the ``HEART for Women Act''.
  
  SEC. 2. REPORTING OF DATA IN APPLICATIONS FOR DRUGS, BIOLOGICS, AND 
                DEVICES.
  
      (a) In General.--The Comptroller General of the United States shall 
  conduct a study investigating the extent to which sponsors of clinical 
  studies of investigational drugs, biologics, and devices and sponsors 
  of applications for approval or licensure of new drugs, biologics, and 
  devices comply with Food and Drug Administration requirements and 
  follow guidance for presentation of clinical study safety and 
  effectiveness data by sex, age, and racial subgroups.
      (b) Report by GAO.--
              (1) Submission.--Not later than 12 months after the date of 
          the enactment of this Act, the Comptroller General shall 
          complete the study under subsection (a) and submit to the 
          Committee on Energy and Commerce of the House of 
          Representatives and the Committee on Health, Education, Labor, 
          and Pensions of the Senate a report on the results of such 
          study.
              (2) Contents.--The report required by paragraph (1) shall 
          include each of the following:
                      (A) A description of the extent to which the Food 
                  and Drug Administration assists sponsors in complying 
                  with the requirements and following the guidance 
                  referred to in subsection (a).
                      (B) A description of the effectiveness of the Food 
                  and Drug Administration's enforcement of compliance 
                  with such requirements.
                      (C) An analysis of the extent to which females, 
                  racial and ethnic minorities, and adults of all ages 
                  are adequately represented in Food and Drug 
                  Administration-approved clinical studies (at all 
                  phases) so that product safety and effectiveness data 
                  can be evaluated by gender, age, and racial subgroup.
                      (D) An analysis of the extent to which a summary of 
                  product safety and effectiveness data disaggregated by 
                  sex, age, and racial subgroup is readily available to 
                  the public in a timely manner by means of the product 
                  label or the Food and Drug Administration's Web site.
                      (E) Appropriate recommendations for--
                              (i) modifications to the requirements and 
                          guidance referred to in subsection (a); or
                              (ii) oversight by the Food and Drug 
                          Administration of such requirements.
      (c) Report by HHS.--Not later than 6 months after the submission by 
  the Comptroller General of the report required under subsection (b), 
  the Secretary of Health and Human Services shall submit to the 
  Committee on Energy and Commerce of the House of Representatives and 
  the Committee on Health, Education, Labor, and Pensions of the Senate a 
  response to such report, including a corrective action plan as needed 
  to respond to the recommendations in such report.
      (d) Biennial Reports by the Food and Drug Administration.--Not 
  later than 2 years after the date of enactment of this Act, and every 2 
  years thereafter--
              (1) the Director of the Office of Women's Health of the 
          Food and Drug Administration shall submit to the Committee on 
          Energy and Commerce of the House of Representatives and the 
          Committee on Health, Education, Labor, and Pensions of the 
          Senate, a report that includes each of the elements described 
          in subparagraphs (A) through (E) of subsection (b)(2), with 
          respect to women's health; and
              (2) the Director of the Office of Minority Health of the 
          Food and Drug Administration shall submit to such Committees a 
          report that includes each of such elements, with respect to 
          minority health.
      (e) Definitions.--In this section:
              (1) The term ``biologic'' has the meaning given to the term 
          ``biological product'' in section 351(i) of the Public Health 
          Service Act (42 U.S.C. 262(i)).
              (2) The term ``device'' has the meaning given to such term 
          in section 201(h) of the Federal Food, Drug, and Cosmetic Act 
          (21 U.S.C. 321(h)).
              (3) The term ``drug'' has the meaning given to such term in 
          section 201(g) of the Federal Food, Drug, and Cosmetic Act (21 
          U.S.C. 321(g)).
  
  SEC. 3. REPORTING ON QUALITY OF AND ACCESS TO CARE FOR WOMEN WITH 
                CARDIOVASCULAR DISEASES.
  
      Part P of title III of the Public Health Service Act (42 U.S.C. 
  280g et seq.) is amended by adding at the end the following:
  
  ``SEC. 399V-6. REPORTING ON QUALITY OF AND ACCESS TO CARE FOR WOMEN 
                WITH CARDIOVASCULAR DISEASES.
  
      ``Not later than September 30, 2014, and annually thereafter, the 
  Secretary of Health and Human Services shall prepare and submit to the 
  Congress a report on the quality of and access to care for women with 
  heart disease, stroke, and other cardiovascular diseases. The report 
  shall contain recommendations for eliminating disparities in, and 
  improving the treatment of, heart disease, stroke, and other 
  cardiovascular diseases in women.''.
  
  SEC. 4. EXTENSION OF WISEWOMAN PROGRAM.
  
      Section 1509 of the Public Health Service Act (42 U.S.C. 300n-4a) 
  is amended--
              (1) in subsection (a)--
                      (A) by striking the heading and inserting ``In 
                  General.--''; and
                      (B) in the matter preceding paragraph (1), by 
                  striking ``may make grants'' and all that follows 
                  through ``purpose'' and inserting the following: ``may 
                  make grants to such States for the purpose'';
              (2) in subsection (d)(1), by striking ``there are 
          authorized'' and all that follows through the period and 
          inserting ``there are authorized to be appropriated $23,000,000 
          for fiscal year 2012, $25,300,000 for fiscal year 2013, 
          $27,800,000 for fiscal year 2014, $30,800,000 for fiscal year 
          2015, and $34,000,000 for fiscal year 2016.''; and
              (3) by adding at the end the following new subsection:
      ``(e) Study.--
              ``(1) The Secretary shall (directly or through grants or 
          contracts) conduct a study of the impact of the Patient 
          Protection and Affordable Care Act on the preventive health 
          services, referrals, and follow-up services described in 
          subsection (a).
              ``(2) Not later than 18 months after the date of enactment 
          of this subsection, the Secretary shall submit to the Committee 
          on Energy and Commerce of the House of Representatives and to 
          the Committee on Health, Education, Labor, and Pensions of the 
          Senate a report containing the results of the study under 
          paragraph (1) and recommendations for improving the provision 
          of preventive health services, referrals, and follow-up 
          services described in paragraph (1) to women eligible for such 
          services under grants funded under this section.''.
target: Heart Disease Education, Analysis, Research, and Treatment for Women Act or the HEART for Women Act - Directs the Comptroller General to report on whether the presentation of clinical study safety and effectiveness data by sex, age, and racial subgroups complies with Food and Drug Administration (FDA) requirements. Requires the Secretary of Health and Human Services (HHS) to submit a response to such report, including a corrective action plan as needed.
  
   Requires the Director of the Office of Women's Health of FDA to report on the compliance of clinical studies of women's health with such FDA requirements, including requirements regarding: (1) the adequacy of representation of females, racial and ethnic minorities, and adults of all ages in approved clinical studies; and (2) the extent to which a summary of product safety and effectiveness data disaggregated by sex, age, and racial subgroup is available to the public. Requires the Director of the Office of Minority Health of FDA to submit a report that includes such information with respect to clinical studies of minority health.
  
  Amends the Public Health Service Act to require the Secretary to report on the quality of, and access to, care for women with heart disease, stroke, and other cardiovascular diseases and to include recommendations for eliminating disparities in, and improving the treatment of, heart disease, stroke, and other cardiovascular diseases in women.
  
  Reauthorizes a program to award grants for preventive heath services and referrals for medical treatment for women through entities that are screening women for breast or cervical cancer. Requires the Secretary to study the impact of the Patient Protection and Affordable Care Act on such services and make recommendations for improvement in the provision of preventive health services, referrals, and followup services to women eligible for such services.
feat_title: To amend the Public Health Service Act to improve women's health by prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women, and for other purposes.